Insider buying · SEC Form 4

ASND insider buying

Open-market purchases of Ascendis Pharma A/S (ASND) stock by its own executives, directors and 10% owners — every Form 4 buy of $250K or more that SPX Lens's daily insider scan has recorded, newest first.

1insider buy on record
$493Kbought in total
1insider
0by CEOs, CFOs and other chiefs
Aug 19, 2026latest scan with a buy

Every recorded buy

ScanInsiderValueSharesAvg priceTypeFiled
Aug 19, 2026Jean Jacques BienaiméDirector$493K2,000$246.33AddedAug 18, 2026
Form 4 ↗
Two open-market purchases on Aug 14: 1,100 shares at $245.85 avg ($270,435) and 900 shares at $246.91 avg ($222,219). Total 2,000 shares at ~$246.38 avg. Post-transaction: 2,900 direct shares. No 10b5-1 plan.

Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.

SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free, and a new scan is posted every trading day. How to read insider buying →

See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.

Open the live chartOpen in the Stocks tab

© SPX Lens · About · Terms · Privacy — for educational purposes only, not financial advice.